Dabur Pharma inks pact with Thailand’s GPO

India’s leading oncology player Dabur Pharma Limited has signed an agreement with Government Pharmaceutical Organization (GPO) of Thailand for generic version of one of its key anticancer products.

The agreement with GPO has been signed for generic Docetaxel Injection at a very special price. Under the pact, Thailand will import the product and distribute it among 'needy patients' as part of Thailand's efforts to provide access to essential medicines for low-income patients.

Dabur Pharma Limited engages in the development, manufacture, and marketing of oncology drugs in India. It offers active pharmaceutical ingredients, injectables, intermediates, and oral dosage forms. The company’s has operations in Asia Pacific, Commonwealth of Independent States, Latin America, North America, and the European Union.

The company reported 8% decrease in net profit at Rs 8.26 crore for the quarter to December 2007. Its sales decreased by 15% to Rs 65.01 crore.

Regions: